A Phase 1/2 interventional study of CC-99282 and Rituximab in Lymphoma, Non-Hodgkin, sponsored by Celgene. Active, not recruiting at 66 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb — 2 open to participants now, 5 under way, none of them phase 3. Lymphoma, Non-Hodgkin · Bristol-Myers Squibb.
Among the 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb, this one is the 3rd largest by planned enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2019, is one of 9 in phase 1/2, and was the 37th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →2 of the 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Chile, China and 12 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Germany, Japan and 1 more country
By country, each count listing its studies:
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 23 · Phase 3 6
First in 2004; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 438 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 58 across the 46 interventional studies, 43 across the 4 observational. Of the 42 that completed or were terminated, 25 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
3 of the studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05688475Bristol-Myers SquibbA Rollover Study of CC-122 | 2026-11-30 |
| NCT03930953CelgeneA Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) | 2027-04-07 |
| NCT06090539Bristol-Myers SquibbA Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | 2027-10-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
Participants with relapsed or refractory non-Hodgkin's lymphomas (R/R NHL) who have failed at least 2 lines of therapy (or have received at least one prior line of standard therapy and are not eligible for any other therapy).
The dose escalation will evaluate the safety and tolerability of escalating doses of CC-99282 in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and/or relapsed or refractory follicular lymphoma (R/R FL) participants to determine the maximum tolerated dose (MTD) of CC-99282 as monotherapy.
The dose expansion will further evaluate the safety and preliminary efficacy of single agent CC-99282 or the safety and preliminary efficacy of CC-99282 in combination with anti-lymphoma agents in participants with R/R DLBCL and NHL.
Part B Cohort B will further evaluate the potential effects of food on the PK and safety of CC-99282.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CC-99282
Drug: CC-99282 · Drug: Rituximab · Drug: Obinutuzumab · Drug: Tafasitamab · Drug: Valemetostat
Specified dose on specified days
Also known as: BMS-986369
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Incidence of Adverse Events (AEs)
Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
Number of participants with laboratory abnormalities
Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
Number of participants with vital sign abnormalities
Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities
Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
Number of participants with left ventricular ejection fraction (LVEF) assessment abnormalities
Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
Number of participants with physical examination abnormalities
Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
Dose Limiting Toxicity (DLT)
Time frame: Up to 28 days in Cycle 1
Maximum tolerated dose (MTD)
Time frame: Up to 28 days in cycle 1
Pharmacokinetics - Maximum plasma concentration of drug (Cmax)
Time frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days)
Pharmacokinetics - Area under the plasma concentration-time curve (AUC)
Time frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days)
Pharmacokinetics - Time to peak (maximum) plasma concentration (Tmax)
Time frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days)
Pharmacokinetics - Terminal-phase elimination half-life (T-HALF)
Time frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days)
Pharmacokinetics - Apparent total body clearance of the drug from the plasma (CLT/F)
Time frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days)
Pharmacokinetics: Apparent volume of distribution (Vz/F)
Time frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days)
Objective response rate (ORR)
Defined as the percent of subjects whose best response is Complete Response (CR) or Partial Response (PR). Determined by the Lugano Classification for NHL response criteria
Time frame: Up to approximately 6 years
Time to response (TTR)
Determined by the Lugano Classification for NHL response criteria
Time frame: Up to approximately 6 years
Duration of response (DoR)
Determined by the Lugano Classification for NHL response criteria
Time frame: Up to approximately 6 years
Progression free survival (PFS)
Time from first dose of CC-99282 to the first occurrence of disease progression or death from any cause Determined by the Lugano Classification for NHL response criteria
Time frame: Up to approximately 6 years
Overall survival (OS)
Time from first dose of CC-99282 to death from any cause Determined by the Lugano Classification for NHL response criteria
Time frame: Up to approximately 6 years
ORR
Defined as the percent of subjects whose best response is Complete Response (CR) or Partial Response (PR). Determined using the modified International PCNSL Collaborative Group (IPCG) criteria
Time frame: Up to approximately 4 years
TTR
Determined using the modified International PCNSL Collaborative Group (IPCG) criteria
Time frame: Up to approximately 4 years
DOR
Determined using the modified International PCNSL Collaborative Group (IPCG) criteria
Time frame: Up to approximately 4 years
PFS
Determined using the modified International PCNSL Collaborative Group (IPCG) criteria
Time frame: Up to approximately 4 years
OS
Determined using the modified International PCNSL Collaborative Group (IPCG) criteria
Time frame: Up to approximately 4 years
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started May 2019 (actual). Primary completion is estimated for Apr 2027, 94 months after the start.
Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's planned 94 months is above that.
Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Golcadomide